Ichorcumab - Janssen Pharmaceuticals

Drug Profile

Ichorcumab - Janssen Pharmaceuticals

Alternative Names: JNJ 9375; JNJ-375; JNJ-64179375

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge University Hospitals; University of Cambridge
  • Developer Janssen Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombosis

Most Recent Events

  • 26 Sep 2017 Phase-I clinical trials in Thrombosis (In volunteers) in United Kingdom (IV)
  • 26 Sep 2017 Janssen Biotech completes a phase I trial in Thrombosis (In volunteers) in United Kingdom
  • 26 Aug 2017 Pharmacodynamics data from a phase I trial in Thrombosis presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology (ESC-Card-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top